Merrimack Pharma (MACK) Misses Q3 EPS by 65c, Initiate Corporate Restructuring

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Merrimack Pharma (MACK) Misses Q3 EPS by 65c, Initiate Corporate Restructuring

Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review

November 7, 2018 6:45 AM EST

CAMBRIDGE, Mass., Nov. 7, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a research and clinical development oncology company focused on biomarker-defined cancers, today announced its third quarter 2018 financial results for the period ended September 30, 2018 and provided a strategic update.

"Following a comprehensive review of our drug candidate pipeline, we have determined that a corporate restructuring provides the best path forward to reduce operational costs and maximize value. Naturally, this step was the result of an extremely difficult decision and we regret its impact on the affected members of our team,... More